Development Diligence Obligations. AstraZeneca shall use Commercially Reasonable Efforts to apply for and obtain Regulatory Approval of the Collaboration Product in the ROW Territory, and Xxxxxxxxx shall use Commercially Reasonable Efforts to apply for and obtain Regulatory Approval of the Collaboration Product in China, in each case, as soon as reasonably practicable. AstraZeneca shall use Commercially Reasonable Efforts to Develop or procure the Development of any Diagnostic Products reasonably necessary to Commercialize the Collaboration Products and to apply for and obtain Regulatory Approval of such Diagnostic Products in the Territory as soon as reasonably practicable.
Development Diligence Obligations. During the Term, Licensee will (a) use Commercially Reasonable Efforts to Develop and obtain Regulatory Approval of a TAK-385 Licensed Product in the Women’s Health Field in the United States [***], (b) use Commercially Reasonable Efforts to Develop and obtain Regulatory Approval of a TAK-385 Licensed Product in the Men’s Health Field in Japan and the United States, (c) use Commercially Reasonable Efforts to [***] set forth in the TAK-385 Development Plan, (d) use Commercially Reasonable Efforts to [***], and (e) [***]. In addition, during the Term, Licensee will use Commercially Reasonable Efforts to Develop and obtain Regulatory Approval of a TAK-448 Licensed Product in the Field in one country or jurisdiction in the Licensee Territory.
Development Diligence Obligations. On a Research Program-by-Research Program basis, following Xxxxxxx’x exercise of an Option with respect to a Research Program pursuant to Section 3.2 (Option Exercise), Xxxxxxx will use Commercially Reasonable Efforts to [***]. Xxxxxxx will have no other diligence obligations under this Agreement with respect to the Development or Regulatory Approval of any Compounds or Products.
Development Diligence Obligations. If Biogen has commenced an IND-Enabling Study for a Development Candidate directed to a Collaboration Target in the United States or one Major European Market, then Biogen, itself or through its Affiliates, Sublicensees, or Subcontractors, will use Commercially Reasonable Efforts to Develop and seek Regulatory Approval for at least [***] directed to such Collaboration Target in the United States or [***] Major European Market. Biogen will have no other diligence obligations under this Agreement with respect to the Development or Regulatory Approval of any Development Candidates or Products.
Development Diligence Obligations. Kiniksa shall use Commercially Reasonable Efforts to Develop the Product in the Kiniksa Field in the Territory. Without limiting the foregoing, Kiniksa shall use Commercially Reasonable Efforts to undertake and perform the Development activities set forth in the then-current Development Plan for the Product in the Kiniksa Field in a timely manner. Kiniksa shall conduct all such activities in compliance with Applicable Laws.
Development Diligence Obligations. Shionogi shall use Commercially Reasonable Efforts to Develop Products in each Specified Territory (it being understood that, for the avoidance of doubt, a breach of the foregoing obligation in any country within a Specified Territory shall not be considered a breach or violation of this Section 4.1.4 if such breach is not material to such Specified Territory taken as a whole). Without limiting Egalet’s obligations under Section 4.1.1, each Party shall use Commercially Reasonable Efforts to implement and conduct the Development assigned to such Party under this Agreement, and to cooperate with and provide reasonable support to the other Party in such other Party’s conduct of Development under this Agreement.
Development Diligence Obligations. Without limiting either Party’s obligations under this Article 4 (Development):
Development Diligence Obligations. Xxxxx will be responsible for conducting the activities under the Cross-Territory Clinical Development Plan and the Non-Clinical HAE Development Plan and will use Commercially Reasonable Efforts to carry out such activities. For clarity, Ionis shall not conduct any [***]. Otsuka will be responsible for conducting the activities under the Otsuka Territory-Specific Development Plan [***]. Each Party will conduct all Development activities for which it is responsible under this Agreement in a good scientific manner, in accordance with GLP and GCP, as applicable, and in compliance with Professional Requirements and Applicable Law.
Development Diligence Obligations. Licensee will use [**] to Develop [**] Licensed Product, and obtain Regulatory Approval (and Pricing Approval, if applicable) for [**] Licensed Product in the Field in each of the [**].
Development Diligence Obligations. (a) Subject to the terms and conditions of this Agreement, commencing on the Effective Date, the Parties shall use Commercially Reasonable Efforts to Develop, with the goal of receiving Regulatory Approval, one (1) Licensed Product for the treatment of each of (a) nAMD by means of nAMD Suprachoroidal Treatment, (b) nAMD by means of nAMD Subretinal Treatment, and (c) DR, in each case, in the United States. In addition, subject to the terms and conditions of this Agreement, following the achievement of both of the Initial Registration Enabling Trial Milestone Events, the Parties shall use Commercially Reasonable Efforts to Develop one (1) Licensed Product for the treatment of one (1) Additional Indication in the United States.
